^
Association details:
| Biomarker: | FLT3-ITD mutation + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | revumenib (SNDX-5613) (Menin-MLL inhibitor) + FHD-286 (SMARCA2 inhibitor, SMARCA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4160 Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1
Published date:
11/02/2023
Excerpt:
Finally, co-treatment with FHD-286 and OTX015 or SNDX-5613 (oral gavage) was significantly more effective than each drug alone in reducing the AML burden and overall survival of mice engrafted with a separate PDX model of AML cells with mtNPM1 and FLT3-ITD, without significant toxicity.
